Compounds > t 98475
Page last updated: 2024-12-11

t 98475

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

T 98475: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9874838
CHEMBL ID71917
CHEMBL ID544440
CHEBI ID93085
SCHEMBL ID7497514
MeSH IDM0297227

Synonyms (34)

Synonym
HMS3269M21
BRD-K62221994-001-01-8
gtpl1184
t98475
propan-2-yl 7-[(2,6-difluorophenyl)methyl]-3-[(methyl-(phenylmethyl)amino)methyl]-2-[4-(2-methylpropanoylamino)phenyl]-4-oxothieno[3,2-e]pyridine-5-carboxylate
NCGC00167759-01
L018316
CHEMBL71917 ,
t-98475
CHEMBL544440 ,
bdbm50067485
3-[(benzyl-methyl-amino)-methyl]-7-(2,6-difluoro-benzyl)-2-(4-isobutyrylamino-phenyl)-4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxylic acid isopropyl ester; hydrochloride
t 98475
192887-28-8
SCHEMBL7497514
199119-18-1
7-[(2,6-difluorophenyl)methyl]-4,7-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-thieno[2,3-b]pyridine-5-carboxylic acid 1-methylethyl ester
3-[(benzyl-methyl-amino)-methyl]-7-(2,6-difluoro-benzyl)-2-(4-isobutyrylamino-phenyl)-4-oxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carboxylic acid isopropyl ester
f1klt23o3a ,
isopropyl 3-((benzyl(methyl)amino)methyl)-7-((2,6-difluorophenyl)methyl)-2-(4-(2-methylpropanoylamino)phenyl)-4-oxo-thieno(2,3-b)pyridine-5-carboxylate
propan-2-yl 3-((benzyl(methyl)amino)methyl)-7-((2,6-difluorophenyl)methyl)-2-(4-(2-methylpropanoylamino)phenyl)-4-oxothieno(2,3-b)pyridine-5-carboxylate
unii-f1klt23o3a
thieno(2,3-b)pyridine-5-carboxylic acid, 7-((2,6-difluorophenyl)methyl)-4,7-dihydro-2-(4-((2-methyl-1-oxopropyl)amino)phenyl)-3-((methyl(phenylmethyl)amino)methyl)-4-oxo-, 1-methylethyl ester, hydrochloride
isopropyl 3-(n-benzyl-n-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-(4-isobutyrylaminophenyl)-4-oxothieno(2,3-b)pyridine-5-carboxylate hydrochloride
AKOS024457145
DTXSID90432134
CHEBI:93085
J-012487
FT-0761854
Q27088918
thieno[2,3-b]pyridine-5-carboxylic acid,7-[(2,6-difluorophenyl)methyl]-4,7-dihydro-2-[4-[(2-methyl-1-oxopropyl)amino]phenyl]-3-[[methyl(phenylmethyl)amino]methyl]-4-oxo-,1-methylethyl ester
propan-2-yl 3-[[benzyl(methyl)amino]methyl]-7-[(2,6-difluorophenyl)methyl]-2-[4-(2-methylpropanoylamino)phenyl]-4-oxothieno[2,3-b]pyridine-5-carboxylate
CS-0028826
HY-107533

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Uracils bearing a side chain derived from phenylglycinol at the 3-position were shown to be orally bioavailable in monkeys."( 3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in
Acevedo, O; Bonneville, AK; Bozigian, H; Chen, C; Chen, T; Gao, Y; Gross, TD; Guo, Z; Ling, N; Liu, XJ; Reinhart, GJ; Rowbottom, MW; Saunders, J; Struthers, RS; Tucci, FC; Xie, Q; Zhu, YF, 2005)		0.33
" Starting with the thienopyridin-4-one derivative 26d (T-98475) an optimization study was performed, which resulted in the identification of a highly potent and orally bioavailable LHRH receptor antagonist, 3-(N-benzyl-N-methylaminomethyl)-7-(2,6-difluorobenzyl)-4,7-dihydro-2-[4-(1-hydroxy-1-cyclopropanecarboxamido)phenyl]-5-isobutyryl-4-oxothieno[2,3-b]pyridine (33c)."( Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
Cho, N; Endo, S; Furuya, S; Harada, M; Hayase, Y; Imada, T; Imaeda, T; Kasai, S; Matsumoto, H; Sasaki, S; Suzuki, N, 2006)		0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (2)

ClassDescription
thienopyridineAny organic heterobicyclic compound whose skeleton results from the formal ortho-fusion of any bond of a pyridine with any bond of a thiophene.
isopropyl esterAny carboxylic ester resulting from the formal condensation of a carboxylic acid with the hydroxy group of propan-2-ol.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gonadotropin-releasing hormone receptorHomo sapiens (human)IC50 (µMol)0.00800.00010.12895.2000AID1416689; AID241563; AID267082; AID267083; AID267085; AID267086; AID407893; AID74276; AID74407
Gonadotropin-releasing hormone receptorHomo sapiens (human)Ki0.00020.00010.00290.0190AID1416689; AID1416692; AID74419
Gonadotropin-releasing hormone receptorRattus norvegicus (Norway rat)IC50 (µMol)0.04810.00030.15422.0000AID242050; AID267084; AID407895; AID74431; AID74551
Gonadotropin-releasing hormone receptorRattus norvegicus (Norway rat)Ki0.06000.00383.51866.5000AID74573
Gonadotropin-releasing hormone receptorMacaca mulatta (Rhesus monkey)IC50 (µMol)0.00400.00060.00230.0040AID407894
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
gonadotropin secretionGonadotropin-releasing hormone receptorHomo sapiens (human)
cellular response to gonadotropin-releasing hormoneGonadotropin-releasing hormone receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayGonadotropin-releasing hormone receptorHomo sapiens (human)
cellular response to hormone stimulusGonadotropin-releasing hormone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (2)

Processvia Protein(s)Taxonomy
peptide bindingGonadotropin-releasing hormone receptorHomo sapiens (human)
gonadotropin-releasing hormone receptor activityGonadotropin-releasing hormone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
plasma membraneGonadotropin-releasing hormone receptorHomo sapiens (human)
membraneGonadotropin-releasing hormone receptorHomo sapiens (human)
plasma membraneGonadotropin-releasing hormone receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID74419Binding affinity towards human gonadotropin-releasing hormone receptor2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists.
AID267082Inhibition of [125I]leuprorelin binding to human recombinant LHRH receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID267083Inhibition of [125I]leuprorelin binding to monkey recombinant LHRH receptor expressed in CHO cells2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID1416689Antagonist activity at N-terminal FLAG-tagged human full-length GnRHR expressed in HEK293T cells assessed as inhibition of GnRH-induced calcium mobilization preincubated for 15 mins followed by agonist addition by FLIPR assay2017MedChemComm, Oct-01, Volume: 8, Issue:10
Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor.
AID267087Inhibition of LHRH-stimulated arachidonic acid release in CHO cells expressing monkey LHRH receptor2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID267084Inhibition of [125I]leuprorelin binding to rat anterior pituitary LHRH receptor2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID74276Ability of compound to inhibit [125I-Tyr5,DLeu6,NMeLeu7,Pro9-NEt]GnRH agonist binding to the cloned human Gonadotropin-releasing hormone receptor was evaluated2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and initial structure-activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.
AID267086Inhibition of LHRH-stimulated arachidonic acid release in CHO cells expressing human LHRH receptor2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID241563Inhibition of Human gonadotropin-releasing hormone receptor2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in
AID407893Binding affinity at human GnRH receptor2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Non-peptide gonadotropin-releasing hormone receptor antagonists.
AID242050Inhibition of Rat gonadotropin-releasing hormone receptor(moderate affinity)2005Journal of medicinal chemistry, Feb-24, Volume: 48, Issue:4
3-[(2R)-Amino-2-phenylethyl]-1-(2,6-difluorobenzyl)-5-(2-fluoro-3-methoxyphenyl)- 6-methylpyrimidin-2,4-dione (NBI 42902) as a potent and orally active antagonist of the human gonadotropin-releasing hormone receptor. Design, synthesis, and in vitro and in
AID267085Inhibition of [125I]leuprorelin binding to monkey anterior pituitary LHRH receptor2006Journal of medicinal chemistry, Jun-29, Volume: 49, Issue:13
Design, synthesis, and structure-activity relationships of thieno[2,3-b]pyridin-4-one derivatives as a novel class of potent, orally active, non-peptide luteinizing hormone-releasing hormone receptor antagonists.
AID74431Ability of compound to inhibit [125I-Tyr5,DLeu6,NMeLeu7,Pro9-NEt]GnRH agonist binding to the rat Gonadotropin-releasing hormone receptor was evaluated2002Bioorganic & medicinal chemistry letters, Aug-19, Volume: 12, Issue:16
Synthesis and initial structure-activity relationships of a novel series of imidazolo[1,2-a]pyrimid-5-ones as potent GnRH receptor antagonists.
AID74551Binding affinity against gonadotropin-releasing hormone receptor of rat2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists.
AID407894Binding affinity at monkey GnRH receptor2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Non-peptide gonadotropin-releasing hormone receptor antagonists.
AID74407Inhibitory activity against human GnRH receptor using des-Gly10[125I]Tyr5, D-Leu, NMeLeu, Pro-NEt]GnRH radioligand2002Bioorganic & medicinal chemistry letters, Feb-11, Volume: 12, Issue:3
Initial structure-activity relationship studies of a novel series of pyrrolo[1,2-a]pyrimid-7-ones as GnRH receptor antagonists.
AID407895Binding affinity at rat GnRH receptor2008Journal of medicinal chemistry, Jun-26, Volume: 51, Issue:12
Non-peptide gonadotropin-releasing hormone receptor antagonists.
AID74573Binding affinity towards rat Gonadotropin-releasing hormone receptor2003Bioorganic & medicinal chemistry letters, Oct-20, Volume: 13, Issue:20
Synthesis and structure-activity relationships of thieno[2,3-d]pyrimidine-2,4-dione derivatives as potent GnRH receptor antagonists.
AID1416692Displacement of [125I]leuprorelin from human GnRHR expressed in CHO cell membranes after 60 mins by gamma-ray counting method2017MedChemComm, Oct-01, Volume: 8, Issue:10
Small molecule piperazinyl-benzimidazole antagonists of the gonadotropin-releasing hormone (GnRH) receptor.
AID1346002Human GnRH1 receptor (Gonadotrophin-releasing hormone receptors)1998Journal of medicinal chemistry, Oct-22, Volume: 41, Issue:22
Discovery of a novel, potent, and orally active nonpeptide antagonist of the human luteinizing hormone-releasing hormone (LHRH) receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (9.09)18.2507
2000's7 (63.64)29.6817
2010's1 (9.09)24.3611
2020's2 (18.18)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.32

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.32 (24.57)
Research Supply Index2.48 (2.92)
Research Growth Index4.80 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.32)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		2.420mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
gonadotropin-releasing hormone
relisorm L: Gonadotropin-Releasing Hormone analog. gonadorelin : A ten-membered synthetic oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, glycyl, leucyl, arginyl, prolyl and glycinamide residues joined in sequence.		1.9910oligopeptide;
peptide hormone		gonadotropin releasing hormone agonist
leuprolide
Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.		2.4120oligopeptideanti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist
tak 013
[no description available]		3.5320
ag045572
[no description available]		3.5820
nbi 42902
[no description available]		3.5320
ConditionIndicatedRelationship StrengthStudiesTrials
Congenital Zika Syndrome
[description not available]		02.2510
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.2510
Zika Virus Infection
A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.		02.2510